期刊文献+

Correlation of human epidermal growth factor receptor protein expression and colorectal cancer 被引量:2

Correlation of human epidermal growth factor receptor protein expression and colorectal cancer
下载PDF
导出
摘要 AIM:To investigate the correlation between human epidermal growth factor receptor(HER-2) protein expression and colorectal cancer(CRC) using a casecontrol study and meta-analysis.METHODS:Tumor tissue specimens from 162 CRC patients were selected for the case group.Fifty cases were randomly selected,and normal CRC tissue at least 10 cm away from the tumor margins of these cases was used to generate the control group.The expression of the HER-2 protein in the 162 CRC tissue samples and the 50 adjacent normal mucosa tissue samples was detected via immunohistochemistry.The experimental data were analyzed using SPSS 18.0software,and R software version 3.1.0 was utilized for further verification.RESULTS:The expression of HER-2 protein in the 162 CRC tissue samples was significantly higher than in the normal tissue specimens.The data showed that the expression of HER-2 in CRC was related to the Dukes' stage,the depth of invasion and lymph node metastasis.The HER-2-positive patients had lower 3-and 5-year OS rates than the HER-2-negative patients,but there was no significant difference.However,there was a statistically significant difference in the 3- and5-year disease-free survival(DFS) rates of HER-2-positive and HER-2-negative patients.The results of the meta-analysis showed that the expression of HER-2in CRC patients was statistically significantly increased over that of healthy people.The 3-year DFS rate in HER-2-positive patients was markedly lower than that in HER-2-negative patients.CONCLUSION:Down-regulation of HER-2 expression might be a dependable strategy for CRC therapy. AIM:To investigate the correlation between human epidermal growth factor receptor(HER-2) protein expression and colorectal cancer(CRC) using a casecontrol study and meta-analysis.METHODS:Tumor tissue specimens from 162 CRC patients were selected for the case group.Fifty cases were randomly selected,and normal CRC tissue at least 10 cm away from the tumor margins of these cases was used to generate the control group.The expression of the HER-2 protein in the 162 CRC tissue samples and the 50 adjacent normal mucosa tissue samples was detected via immunohistochemistry.The experimental data were analyzed using SPSS 18.0software,and R software version 3.1.0 was utilized for further verification.RESULTS:The expression of HER-2 protein in the 162 CRC tissue samples was significantly higher than in the normal tissue specimens.The data showed that the expression of HER-2 in CRC was related to the Dukes' stage,the depth of invasion and lymph node metastasis.The HER-2-positive patients had lower 3-and 5-year OS rates than the HER-2-negative patients,but there was no significant difference.However,there was a statistically significant difference in the 3- and5-year disease-free survival(DFS) rates of HER-2-positive and HER-2-negative patients.The results of the meta-analysis showed that the expression of HER-2in CRC patients was statistically significantly increased over that of healthy people.The 3-year DFS rate in HER-2-positive patients was markedly lower than that in HER-2-negative patients.CONCLUSION:Down-regulation of HER-2 expression might be a dependable strategy for CRC therapy.
出处 《World Journal of Gastroenterology》 SCIE CAS 2015年第28期8687-8696,共10页 世界胃肠病学杂志(英文版)
关键词 Human EPIDERMAL growth factor receptor COLORECTAL cancer IMMUNOHISTOCHEMISTRY BIOMARKER Therapy CASE-CONTROL study Meta-analysis Human epidermal growth factor receptor Colorectal cancer Immunohistochemistry BiomarkerTherapy Case-control study Meta-analysis
  • 相关文献

参考文献1

二级参考文献6

  • 1Yung-Jue Bang,Eric Van Cutsem,Andrea Feyereislova,Hyun C Chung,Lin Shen,Akira Sawaki,Florian Lordick,Atsushi Ohtsu,Yasushi Omuro,Taroh Satoh,Giuseppe Aprile,Evgeny Kulikov,Julie Hill,Michaela Lehle,Josef Rüschoff,Yoon-Koo Kang.Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial[J]. The Lancet . 2010 (9742)
  • 2Joseph P. Connor,Mildred Felder.Ascites from epithelial ovarian cancer contain high levels of functional decoy receptor 3 (DcR3) and is associated with platinum resistance[J].Gynecologic Oncology.2008(2)
  • 3GabrieleMild,FelixBachmann,Jean‐LouisBoulay,KatharinaGlatz,UrbanLaffer,AdamLowy,UrsMetzger,JürgenReuter,LuigiTerracciano,RichardHerrmann,ChristophRochlitz.DCR3 locus is a predictive marker for 5‐fluorouracil‐based adjuvant chemotherapy in colorectal cancer[J].Int J Cancer.2002(3)
  • 4Helen Han,Rodney J. Landreneau,Tibetha S. Santucci,Ming Y. Tung,Robin S. Macherey,Stanley E. Shackney,Charles D. Sturgis,Stephen S. Raab,Jan F. Silverman.Prognostic value of immunohistochemical expressions of p53, HER-2/ neu, and bcl-2 in stage I non[ndash ]small-cell lung cancer[J].Human Pathology.2002(1)
  • 5Yasushi Takahama,Yukishige Yamada,Koji Emoto,Heisuke Fujimoto,Tomoyoshi Takayama,Masatoh Ueno,Hideki Uchida,Shuya Hirao,Takashi Mizuno,Yoshiyuki Nakajima.The prognostic significance of overexpression of the decoy receptor for Fas ligand (DcR3) in patients with gastric carcinomas[J].Gastric Cancer.2002(2)
  • 6Jia-Lin Yang PhD,Kim T. Ow MSc,Pamela J. Russell PhD,John M. Ham MD,Dr. Philip J. Crowe PhD.Higher expression of oncoproteins c-myc, c-erbB-2/neu, PCNA, and p53 in metastasizing colorectal cancer than in nonmetastasizing tumors[J].Annals of Surgical Oncology.1996(6)

共引文献2

同被引文献8

引证文献2

二级引证文献2

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部